Does the concept of lower-risk myelodysplastic syndrome need to be revisited?

Leuk Res. 2015 Oct;39(10):1003-5. doi: 10.1016/j.leukres.2015.06.010. Epub 2015 Jun 22.

Authors

Jose F Falantes¹, Guillermo Garcia-Manero²

Affiliations

¹ Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto de BioMedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Spain. Electronic address: [email protected].
² Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

PMID: 26198376
DOI: 10.1016/j.leukres.2015.06.010

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use
Humans
Myelodysplastic Syndromes / drug therapy
Myelodysplastic Syndromes / mortality*
Prognosis
Risk

Substances

Antineoplastic Agents